Key facts
- This page summarizes Andrew Dudum's Form 4 filing for Hims & Hers Health, Inc. (HIMS).
- 13 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 20 Oct 2025, 16:42.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Sale
Sale
Options Exercise
Sale
Options Exercise
Sale
Sale
Sale
Sale
Sale
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.
Footnote F2
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.50 - $62.87. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Footnote F3
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.215 - $63.13. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Footnote F4
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $63.31 - $63.59. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Footnote F5
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.25 - $62.94. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Footnote F6
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.22 - $63.18. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Footnote F7
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $63.25 - $63.63. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Footnote F8
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.22 - $63.20. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Footnote F9
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $63.26 - $63.47. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Footnote F10
Prior to the Company's business combination transaction in 2021, the option represented the right to purchase 7,166,182 shares of Hims, Inc. with an exercise price of $1.10. Following the Company's business combination transaction in 2021, the option converted into the right to purchase 3,246,139 shares of the Company with an exercise price of $2.43. 100% of the shares subject to the option vested upon certain specified thresholds met in 2021.
Footnote F11
The Stock Option was received in exchange for an option to purchase 3,583,091 shares of Class A Common Stock of Hims, Inc., with an exercise price of $1.10, in connection with the Merger. 1/48 of the shares subject to the Stock Option vest when the Reporting Person completes each month of continuous Service beginning March 13, 2020.